Navigation Links
Safety of Labor-Delaying Drugs Questioned
Date:3/6/2009

The dilemma, researchers say, is whether or not to treat at all

FRIDAY, March 6 (HealthDay News) -- Certain drugs used to delay preterm labor can cause serious complications in women, a European study finds.

Doctors use tocolytic drugs to delay labor for up to 48 hours. In this way, they gain time to allow steroids to hasten fetal lung development. These delays also enable the expectant mother to be transferred to a medical facility with a neonatal intensive care unit, according to background information in the study.

The most widely used tocolytic drugs include beta agonists and nifedipine (which relax smooth muscles, including the uterus), and atosiban and indometacin (which inhibit hormones involved in labor), according to the study. However, the use of these drugs is controversial, because it's not clear whether tocolysis is safe for both mother and baby.

The researchers analyzed the rate of serious complications in 1,920 women treated with tocolytic drugs for preterm labor at 28 hospitals in the Netherlands and Belgium. Atosiban was the most commonly used drug (42 percent), followed by nifedipine (34 percent), beta agonists (14 percent), and indometacin (8 percent).

The overall incidence of adverse effects was 0.7 percent, but combined or single treatment with a beta agonist led to a higher incidence of serious drug reactions. There were no reports of serious reactions when women received atosiban or indometacin.

Combined or single treatment with beta agonists should be discouraged, concluded the researchers. They also recommended further trials to test the safety and effectiveness of nifedipine and atosiban.

In an accompanying editorial, the researchers said their study is a reminder that the decision to use tocolysis shouldn't be taken lightly.

"After 30 years of research, we still do not know whether tocolysis benefits the fetus, so the choice of which drug to use remains a secondary question. The real dilemma is whether or not we should treat at all," they wrote. The long-held belief that "keeping the baby inside longer must be a good thing" needs to be reevaluated, they said.

The study was published March 6 online in the BMJ.

A study released last year found that nifedipine was no more effective than placebo at preventing preterm labor. The U.S. study, which included 71 women, was published in the journal Obstetrics & Gynecology.

More information

The U.S. National Institute on Child Health and Human Development has more about preventing preterm birth.



-- Robert Preidt



SOURCE: BMJ, news release, March 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AdvaMed Available for Comment on Medical Device Safety Act
2. AdvaMed Response to the Medical Device Safety Act
3. bioPoint(TM) PID Wristband Software Improves Patient Identification Accuracy and Safety
4. New Esco White Papers Document Hydrogen Peroxide Decontamination of Biological Safety Cabinets
5. Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment
6. Zebra Technologies Introduces New Soft Infant Wristbands for Improved Safety and Comfort
7. Travel Safety Can Be a Passport to Good Health
8. Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals
9. Johns Hopkins safety team works to eliminate bloodstream infections in the nation and the world
10. Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply
11. Switch to Daylight Savings Time Will Launch First Annual Sedation Dentistry Safety Week Hosted by DOCS Education
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Safety of Labor-Delaying Drugs Questioned
(Date:6/22/2017)... (PRWEB) , ... June 23, 2017 , ... ... in the fight against hunger on June 21, 2017, at the Emeryville Center ... food insecurity and malnutrition around the world. , Rise Against Hunger (formerly Stop ...
(Date:6/20/2017)... ... June 20, 2017 , ... Connance, a leading provider of ... how predictive analytics drive reimbursement optimization, with a focus on denial management and ... , “The traditional approach to denied and underpaid claims leaves money on the ...
(Date:6/20/2017)... ... ... months of negotiations, FaceCradle USA is proud to announce the debut of FaceCradle travel ... product on QVC is something we all worked hard to achieve for many months, and ... million homes in the United States,” said FaceCradle USA President Dylan Doherty. “We can’t wait ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... assessments and consulting services, has published a new eBook titled “ 5 Questions ... Bridge, MSc, Associate Research Analyst on the Genetic Test Evaluation (GTE) team, the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Kenneth Mayer, MD, has been ... (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board in 2016, has co-authored ... Research Director of Fenway Health and Co-Chair of The Fenway Institute, a ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... and Drug Administration (FDA) has notified the Company that the ... Zhejiang, China manufacturing facility has been closed ... of the Warning Letter related to our ... the progress we have made in our ongoing quality and ...
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
Breaking Medicine Technology: